novavax
announces
facility
expansion
support
global
vaccine
development
expands
campus
two
properties
support
vaccine
research
development
manufacturing
business
operations
gaithersburg
globe
newswire
novavax
nasdaq
nvax
biotechnology
company
developing
vaccines
serious
infectious
diseases
today
announced
expansion
maryland
campus
accommodate
company
rapid
growth
works
develop
candidate
vaccine
advance
influenza
vaccine
global
markets
novavax
secured
two
additional
properties
gaithersburg
maryland
support
company
immediate
need
additional
laboratory
office
space
manufacturing
r
business
operations
company
currently
large
pivotal
phase
trial
underway
uk
another
slated
begin
united
states
mexico
november
well
several
phase
trials
ongoing
planning
phases
around
globe
novavax
also
created
global
production
network
enable
manufacturing
rapid
distribution
across
asia
europe
vaccine
approved
use
company
also
reported
positive
phase
data
influenza
vaccine
candidate
nanoflu
earlier
year
novavax
received
billion
funding
vaccine
efforts
including
billion
government
help
address
global
pandemic
million
coalition
epidemic
preparedness
innovations
cepi
expansion
physical
footprint
reflects
novavax
significant
growth
work
rapidly
deliver
vaccine
progress
nanoflu
influenza
vaccine
candidate
regulatory
submission
potential
commercialization
said
stanley
erck
president
ceo
novavax
appreciate
support
partnership
speed
maryland
department
commerce
montgomery
county
city
gaithersburg
enabled
expansion
operations
enhanced
ability
retain
attract
highly
skilled
employees
reinforced
longstanding
commitment
biotechnology
sector
real
estate
tran
actions
novavax
entered
lease
approximately
square
feet
located
quince
orchard
road
gaithersburg
used
manufacturing
research
development
offices
company
immediately
invest
buildout
site
prepare
use
beginning
early
addition
company
affiliate
firstfield
holdings
llc
purchased
parcel
land
firstfield
road
gaithersburg
company
plans
develop
future
accommodate
growth
company
novavax
currently
occupies
approximately
square
feet
office
laboratory
space
gaithersburg
government
support
incentives
maryland
department
commerce
montgomery
county
city
gaithersburg
providing
combination
incentives
including
conditional
loans
grants
tax
credits
enable
expansion
additional
terms
disclosed
vaccine
candidate
engineered
genetic
sequence
virus
causes
disease
created
using
novavax
recombinant
nanoparticle
technology
generate
antigen
derived
coronavirus
spike
protein
contains
novavax
patented
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
contains
purified
protein
antigen
replicate
cause
preclinical
trials
demonstrated
induction
antibodies
block
binding
spike
protein
receptors
targeted
virus
critical
aspect
effective
vaccine
protection
phase
portion
phase
clinical
trial
generally
elicited
robust
antibody
responses
numerically
superior
seen
human
convalescent
sera
also
evaluated
phase
trial
uk
two
ongoing
phase
studies
began
august
phase
trial
south
africa
phase
continuation
australia
novavax
secured
billion
funding
global
coronavirus
vaccine
program
including
million
funding
coalition
epidemic
preparedness
innovations
cepi
nanoflu
recombinant
hemagglutinin
ha
protein
nanoparticle
influenza
vaccine
produced
novavax
insect
cell
baculovirus
system
nanoflu
uses
ha
amino
acid
protein
sequences
recommended
circulating
virus
ha
sequences
nanoflu
contains
novavax
patented
matrixm
adjuvant
novavax
novavax
nasdaq
nvax
biotechnology
company
promotes
improved
health
globally
discovery
development
commercialization
innovative
vaccines
prevent
serious
infectious
diseases
novavax
undertaking
clinical
trials
vaccine
candidate
virus
causes
quadrivalent
influenza
nanoparticle
vaccine
met
primary
objectives
pivotal
phase
clinical
trial
older
adults
vaccine
candidates
incorporate
novavax
proprietary
adjuvant
enhance
immune
response
stimulate
high
levels
neutralizing
antibodies
novavax
leading
innovator
recombinant
vaccines
proprietary
recombinant
technology
platform
combines
power
speed
genetic
engineering
efficiently
produce
highly
immunogenic
nanoparticles
order
address
urgent
global
health
needs
information
visit
connect
us
twitter
linkedin
novavax
statements
statements
herein
relating
future
novavax
ongoing
development
vaccine
adjuvant
products
statements
novavax
cautions
statements
subject
numerous
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
implied
statements
risks
uncertainties
include
identified
heading
risk
factors
novavax
annual
report
form
year
ended
december
quarterly
report
form
period
ended
june
filed
securities
exchange
commission
sec
caution
investors
place
considerable
reliance
statements
contained
press
release
encouraged
read
filings
sec
available
discussion
risks
uncertainties
statements
press
release
speak
date
document
undertake
obligation
update
revise
statements
business
subject
substantial
risks
uncertainties
including
referenced
investors
potential
investors
others
give
careful
consideration
risks
uncertainties
contacts
investors
erika
trahan
media
brandzone
kogs
communication
edna
kaplan
